Patents by Inventor Michael Bristow

Michael Bristow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS INVOLVING BUCINDOLOL FOR THE TREATMENT OF ATRIAL FIBRILLATION
    Publication number: 20230149354
    Abstract: The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the ?1 adrenergic receptor gene.
    Type: Application
    Filed: January 6, 2023
    Publication date: May 18, 2023
    Applicant: ARCA Biopharma, Inc.
    Inventors: Michael BRISTOW, Christopher DUFTON
  • Methods and compositions involving bucindolol for the treatment of atrial fibrillation
    Patent number: 11554107
    Abstract: The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the ?1 adrenergic receptor gene.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: January 17, 2023
    Assignee: ARCA Biopharma, Inc.
    Inventors: Michael Bristow, Christopher Dufton
  • METHODS AND COMPOSITIONS INVOLVING BUCINDOLOL FOR THE TREATMENT OF ATRIAL FIBRILLATION
    Publication number: 20210251962
    Abstract: The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the ?1 adrenergic receptor gene.
    Type: Application
    Filed: February 8, 2021
    Publication date: August 19, 2021
    Applicant: ARCA Biopharma, Inc.
    Inventors: Michael Bristow, Christopher Dufton
  • Methods and compositions involving bucindolol for the treatment of atrial fibrillation
    Patent number: 10925856
    Abstract: The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the ?1 adrenergic receptor gene.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: February 23, 2021
    Assignee: Arca Biopharma, Inc.
    Inventors: Michael Bristow, Christopher Dufton
  • PREDICTION AND TREATMENT OF HEART FAILURE
    Publication number: 20200239957
    Abstract: Chronic activation of the ?-Adrenergic Receptor (?-AR) can have deleterious effects on the heart, and animal models over-expressing the ?-AR develop heart failure. In the classical ?-AR pathway, activation of the receptor results in increased cyclic AMP (cAMP) levels. However, ?-ARs are desensitized in the failing heart and cAMP levels are decreased. Phosphodiesterase 3A (PDE3A) hydrolyzes cAMP in certain subcellular compartments in cardiac myocytes, regulating cAMP levels and subsequent protein kinase A mediated cell signaling. By virtue of being freely diffusable intracellularly and being reduced in failing myocardial tissue, cAMP is reduced in certain important cardiac myocyte subcellular compartments such as the microdomain occupied by phospholamban.
    Type: Application
    Filed: September 9, 2019
    Publication date: July 30, 2020
    Inventors: Michael BRISTOW, Carmen SUCHAROV, Matthew TAYLOR, Dobromir SLAVOV
  • Methods for Treatment with Bucindolol Based on Genetic Targeting
    Publication number: 20180156782
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Application
    Filed: August 30, 2017
    Publication date: June 7, 2018
    Inventors: Stephen B. Liggett, Michael Bristow
  • POLYMORPHISMS IN THE PDE3A GENE
    Publication number: 20170081722
    Abstract: Embodiments of the invention are directed to identifying or treating a patient that would benefit from phosphodiesterase inhibitor therapy.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Inventors: Carmen Sucharov, Michael Bristow, Matthew Taylor, Dobromir Slavov
  • Polymorphisms in the PDE3A gene
    Patent number: 9512481
    Abstract: Embodiments of the invention are directed to identifying or treating a patient that would benefit from phosphodiesterase inhibitor therapy.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: December 6, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Carmen Sucharov, Michael Bristow, Matthew Taylor, Dobromir Slavov
  • PREDICTION AND TREATMENT OF HEART FAILURE
    Publication number: 20160237498
    Abstract: Chronic activation of the ?-Adrenergic Receptor (?-AR) can have deleterious effects on the heart, and animal models over-expressing the ?-AR develop heart failure. In the classical ?-AR pathway, activation of the receptor results in increased cyclic AMP(cAMP) levels. However, ?-ARs are desensitized in the failing heart and cAMP levels are decreased. Phosphodiesterase 3A (PDE3A) hydrolyzes cAMP in certain subcellular compartments in cardiac myocytes, regulating cAMP levels and subsequent protein kinase A mediated cell signaling. By virtue of being freely diffusable intracellularly and being reduced in failing myocardial tissue, cAMP is reduced in certain important cardiac myocyte subcellular compartments such as the microdomain occupied by phospholamban.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 18, 2016
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Michael BRISTOW, Carmen SUCHAROV, Matthew TAYLOR, Dobromir SLAVOV
  • METHODS FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC TARGETING
    Publication number: 20150276717
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Application
    Filed: November 18, 2014
    Publication date: October 1, 2015
    Inventors: Stephen B. Liggett, MICHAEL BRISTOW
  • Methods for treatment with bucindolol based on genetic targeting
    Patent number: 8916603
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: December 23, 2014
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Stephen B. Liggett, Michael Bristow
  • POLYMORPHISMS IN THE PDE3A GENE
    Publication number: 20130203827
    Abstract: Embodiments of the invention are directed to identifying or treating a patient that would benefit from phosphodiesterase inhibitor therapy.
    Type: Application
    Filed: September 13, 2010
    Publication date: August 8, 2013
    Applicant: The Regents of the University of Colorado. a Body
    Inventors: Carmen Sucharov, Michael Bristow, Matthew Taylor, Dobromir Slavov
  • METHODS FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC TARGETING
    Publication number: 20120289573
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Application
    Filed: December 1, 2011
    Publication date: November 15, 2012
    Inventors: Stephen B. Liggett, Michael Bristow
  • Methods for treatment with bucindolol based on genetic targeting
    Patent number: 8093286
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: January 10, 2012
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Stephen B. Liggett, Michael Bristow
  • Methods for treatment with bucindolol based on genetic targeting
    Patent number: 8080578
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: December 20, 2011
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Stephen B. Liggett, Michael Bristow
  • Methods for treatment with bucindolol based on genetic targeting
    Patent number: 7678824
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: March 16, 2010
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Stephen B. Liggett, Michael Bristow
  • Methods for Treatment with Bucindolol Based on Genetic Targeting
    Publication number: 20080227844
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Application
    Filed: August 13, 2007
    Publication date: September 18, 2008
    Inventors: Stephen B. Liggett, Michael Bristow
  • Methods for Treatment with Bucindolol Based on Genetic Targeting
    Publication number: 20080096982
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Application
    Filed: August 13, 2007
    Publication date: April 24, 2008
    Inventors: Stephen Liggett, Michael Bristow
  • Enoximone formulations and their use in the treatment of PDE-III mediated diseases
    Publication number: 20060292213
    Abstract: The present invention provides pharmaceutical formulations of the drug enoximone for use in treatment of disease states in which inhibition of PDE-III may be beneficial.
    Type: Application
    Filed: May 26, 2005
    Publication date: December 28, 2006
    Inventors: Michael Gerber, Rick Gorczynski, Michael Bristow
  • Methods for Treatment with Bucindolol Based on Genetic Targeting
    Publication number: 20060177838
    Abstract: Abstract of the Disclosure The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Application
    Filed: September 14, 2005
    Publication date: August 10, 2006
    Applicants: The Regents of the University of Colorado, The University of Cincinnati
    Inventors: Stephen Liggett, Michael Bristow